VTYX250117P500
- 0.00
- 0.000.00%
Ventyx Biosciences Newsroom
H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating
Express News | HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciencesto Neutral
Ventyx Announces Phase 2 Trials For VTX2735, VTX3232; Obesity Data Expected H2 2025, Parkinson's Data H1 2025; $252.9M Funding Extends To H2 2026
Ventyx Biosciences Highlights Its 2025 Pipeline Strategy
Express News | Ventyx Biosciences: Topline Data From Ongoing Phase 2 Biomarker Trial of Vtx3232 in Participants With Early Parkinson's Disease Expected in H1 2025
Express News | Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on Its Nlrp3 Inhibitor Portfolio
We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
Insider Sale: CHIEF SCIENTIFIC OFFICER of $VTYX (VTYX) Sells 21,119 Shares
Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k
Founder of Ventyx Biosciences Picks Up 30% More Stock
Morgan Stanley Maintains Ventyx Biosciences(VTYX.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Ventyx Biosciences (VTYX)
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 43% Over the Past Week
Neurogene and Ventyx Biosciences Rises After Insider Buying by Executives
Insider Purchase: CEO AND PRESIDENT of $VTYX (VTYX) Buys 238,248 Shares
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Latest 15% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress
Ventyx Biosciences Analyst Ratings
Oppenheimer Maintains Ventyx Biosciences(VTYX.US) With Buy Rating, Cuts Target Price to $9